Gatifloxacin approved

May 1, 2003
Scott M. Whitcup, MD

Scott M. Whitcup is vice president and head of the opthalmology therapeutic area, Allergan.

Ed Edelson

CA-The FDA approval of gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan) marks a milestone as the first fourth-generation fluoroquinolone to enter the ophthalmic market. The therapy for the treatment of bacterial conjunctivitis caused by susceptible strains of bacteria also has a unique mechanism to prevent development of antibiotic resistance, according to Allergan.